US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.09

-0.2000-1.77%

Pre-market: 10.92-0.1700-1.53%07:56 EDT

Volume:121.91K

Turnover:1.35M

Market Cap:3.76B

PE:116.26

High:11.28

Open:11.28

Low:11.04

Close:11.29

52wk High:12.48

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:0.94

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0954

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.71

PE(LYR):-525.59

Loading ...

Overview Company News Filings

Telix Stock And Other Fast Growing Insider Owned Shares Worth A Closer Look

Simply Wall St.

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Simply Wall St.

Jarden Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and CSL (OtherCMXHF)

3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY

Benzinga Earnings

Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says

MT Newswires Live

3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing

Simply Wall St.

Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals Posts Higher Q2 Revenue

MT Newswires Live

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.

RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target

MT Newswires Live

3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction

Simply Wall St.

Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan

MT Newswires Live

Telix Pharmaceuticals Opens Radiopharmaceutical Research, Manufacturing, Treatment Facility in Melbourne

MT Newswires Live

3 ASX Growth Stocks Backed By Insiders That Could Reward Patient Investors

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/TLX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.09,"timestamp":1788206400000,"preClose":11.29,"halted":0,"volume":121913,"hourTrading":{"tag":"盘前","latestPrice":10.92,"preClose":11.09,"latestTime":"07:56 EDT","volume":1076,"amount":11724.937432,"timestamp":1788263797864,"change":-0.17,"changeRate":-0.015329,"amplitude":0.002705},"delay":0,"changeRate":-0.017714791851195687,"floatShares":272000000,"shares":339000000,"eps":0.095386,"marketStatus":"Pre-Mkt","change":-0.2,"latestTime":"09-01 08:06:17 EDT","open":11.28,"high":11.28,"low":11.04,"amount":1352079.7838899998,"amplitude":0.021258,"askPrice":10.92,"askSize":200,"bidPrice":10.66,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.095386,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":11.09,"preHourTrading":{"tag":"盘前","latestPrice":10.92,"preClose":11.09,"latestTime":"07:56 EDT","volume":1076,"amount":11724.937432,"timestamp":1788263797864,"change":-0.17,"changeRate":-0.015329,"amplitude":0.002705},"postHourTrading":{"tag":"盘后","latestPrice":11.06,"preClose":11.09,"latestTime":"19:32 EDT","volume":333,"amount":3706.2,"timestamp":1788219121399,"change":-0.03,"changeRate":-0.002705,"amplitude":0.002705},"volumeRatio":0.9409001724703905},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":0.9409001724703905,"shares":339000000,"dividePrice":0,"high":11.28,"amplitude":0.021258,"preClose":11.29,"low":11.04,"week52Low":6.28,"pbRate":"7.71","psRate":"4.22","week52High":12.48,"institutionHeld":0,"latestPrice":11.09,"eps":0.095386,"divideRate":0,"volume":121913,"delay":0,"ttmEps":0.095386,"open":11.28,"prevYearClose":7.49,"prevWeekClose":11.29,"prevMonthClose":11.09,"prevQuarterClose":11.53,"fiveDayClose":11.68,"twentyDayClose":10.02,"sixtyDayClose":9.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758427200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-31","current":116.264441,"percent":0.277405,"low":-584.49693,"twenty":-444.681415,"median":171.697901,"eighty":244.624606,"high":383.853933,"avg":23.216454,"sd":312.762668,"marketCap":3737797575.74},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96},{"date":"2026-08-28","current":114.191675,"twenty":-444.681415,"median":171.69944,"eighty":244.665977,"marketCap":3825078550.57},{"date":"2026-08-31","current":111.58604,"twenty":-444.681415,"median":171.697901,"eighty":244.624606,"marketCap":3737797575.74}],"updateTime":1788260055765},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654318220","title":"Telix Stock And Other Fast Growing Insider Owned Shares Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2654318220","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654318220?lang=en_us&edition=fundamental","pubTime":"2026-07-24 23:40","pubTimestamp":1784907641,"startTime":"0","endTime":"0","summary":"With central banks watching inflation, energy prices swinging and tariffs back in focus, many investors are looking for companies that are not just growing, but whose leaders have real skin in the game. The Fast Growing Stocks With High Insider Ownership screener targets exactly that kind of stock, combining strong growth potential with management teams that are financially aligned with shareholders. In a world where services sectors are holding up, manufacturing signals are mixed and bond...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-stock-and-other-fast-growing-insider-owned-shares-wort","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-stock-and-other-fast-growing-insider-owned-shares-wort","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MSB.AU","BK7508","TLX","BK7104","PDI.AU","TLX.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654031827","title":"What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2654031827","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654031827?lang=en_us&edition=fundamental","pubTime":"2026-07-24 22:26","pubTimestamp":1784903163,"startTime":"0","endTime":"0","summary":"In July 2026, Telix Pharmaceuticals reported positive early-stage data for its PSMA-targeting therapy TLX591-Tx in advanced prostate cancer, initiated Phase 3 development of TLX250-Tx for clear cell renal cell carcinoma, raised its Fiscal Year 2026 revenue and other income outlook to more than US$1 billion, and entered a collaboration with Regeneron that included an initial US$40 million payment.\nThese updates indicate Telix is moving multiple radiopharmaceutical therapies into later-stage...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-upgraded-us1-billion-fy26","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-upgraded-us1-billion-fy26","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774459","title":"Jarden Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774459?lang=en_us&edition=fundamental","pubTime":"2026-07-24 07:35","pubTimestamp":1784849728,"startTime":"0","endTime":"0","summary":"Jarden analyst Steven Wheen maintained a Buy rating on Telix Pharmaceuticals yesterday and set a price target of A$21.10. The company’s shares clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jarden-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jarden-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653072656","title":"3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2653072656","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653072656?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:28","pubTimestamp":1784809691,"startTime":"0","endTime":"0","summary":"With inflation concerns, higher bond yields, and energy driven price pressures in focus, many investors are looking for stocks where management and analysts are aligned on growth potential. Our Fast Growing Stocks With High Insider Ownership screener highlights companies where insiders hold substantial stakes and outlooks are described as optimistic, which can signal confidence in the business plan and future prospects. In this article, you will see 3 stocks from this screener that stand out...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZYAU.AU","IMLC.AU","TLX.AU","BBOZ.AU","E200.AU","XKO.AU","SLF.AU","BK7145","OZF.AU","IOZ.AU","XJO.AU","EIGA.AU","STW.AU","BK7067","VAS.AU","BEAR.AU","QFN.AU","GIVE.AU","QRE.AU","IISV.AU","DACE.AU","IIGF.AU","PDI.AU","BK4139","VAP.AU","GEAR.AU","OZR.AU","XAO.AU","GLF.AU","TLX","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653794606","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and CSL (OtherCMXHF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653794606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653794606?lang=en_us&edition=fundamental","pubTime":"2026-07-23 07:40","pubTimestamp":1784763606,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals (TLPPF) and CSL (CMXHF). Telix Pharmaceutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-telix-pharmaceuticals-othertlppf-and-csl-othercmxhf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-telix-pharmaceuticals-othertlppf-and-csl-othercmxhf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","BK4585","BK4581","LU0128526141.USD","BK4086","LABU","BK4139","BK4588","LU1169589451.USD","CSL","BK4137","LU0728928796.USD","XBI","TLX","SG9999004303.SGD","LU0029874061.USD","HCSG","CMXHF","XLV","SGXZ23171101.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759165","title":"3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759165","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653759165?lang=en_us&edition=fundamental","pubTime":"2026-07-22 14:24","pubTimestamp":1784701486,"startTime":"0","endTime":"0","summary":"With inflation pressures tied to energy markets, mixed growth signals across regions, and central banks keeping a close eye on every data point, many investors are looking for stocks where management has real skin in the game. The Fast Growing Stocks With High Insider Ownership screener focuses on companies that analysts and insiders both view with optimism, which can help align leadership decisions with shareholder interests. In this article, you will see three stocks from this screener that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","XAO.AU","XJO.AU","PDI.AU","TLX","VAP.AU","OZR.AU","GIVE.AU","GLF.AU","QFN.AU","VAS.AU","QRE.AU","BBOZ.AU","STW.AU","ZYAU.AU","IIGF.AU","OZF.AU","XKO.AU","BK4139","TLX.AU","IOZ.AU","E200.AU","IISV.AU","GEAR.AU","DACE.AU","BEAR.AU","EIGA.AU","IMLC.AU","BK7104","BK7145","SLF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653860407","title":"Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653860407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653860407?lang=en_us&edition=fundamental","pubTime":"2026-07-22 06:00","pubTimestamp":1784671217,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Compugen (CGEN), Telix Pharmaceuticals (TLPPF) and Sarepta Therap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compugen-cgen-telix-pharmaceuticals-othertlppf-and-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compugen-cgen-telix-pharmaceuticals-othertlppf-and-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SRPT","LABU","BK4121","IE00BJT1NW94.SGD","BK4581","IE0009355771.USD","IE00B2B36J28.USD","XLV","LU0029874061.USD","HCSG","BK4588","CGEN","BK4585","IE0002141913.USD","TLPPF","BK4137","SRPU","TLX","BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","XBI","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785616","title":"TLX591-Tx ProstACT SELECT Study Published in Cancers Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785616","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785616?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:00","pubTimestamp":1784667600,"startTime":"0","endTime":"0","summary":"Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with prev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330996/0/en/TLX591-Tx-ProstACT-SELECT-Study-Published-in-Cancers-Journal.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4543","SOC","BK4213","TLX","ASX","BK4141","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653961221","title":"Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2653961221","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653961221?lang=en_us&edition=fundamental","pubTime":"2026-07-21 14:42","pubTimestamp":1784616144,"startTime":"0","endTime":"0","summary":"Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/TLX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653322184","title":"Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322184","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653322184?lang=en_us&edition=fundamental","pubTime":"2026-07-21 14:29","pubTimestamp":1784615387,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  stands to deliver meaningful investment upside and gain significant market share if it can secure regulatory approval for products in the development pipeline, Jefferies said in a Tuesday note.The company launched a prospective phase 3 study to evaluate TLX250-Tx as a potential radiotherapy for relapsed or recurrent clear cell renal cell carcinoma, with the first part of the study expected to enroll up to 40 patients.Following the progression to phase 3, Jefferies' risk-weighting for the trial increased to around 61% from about 21%, while the net present value for the opportunity moved to AU$2.13, the investment firm said.Jefferies raised its full-year 2026 net profit after tax forecast for Telix Pharmaceuticals to $10.6 million from $5.1 million after the company reported second-quarter revenue of $247 million. Telix also guided for 2026 operating revenue to be toward the top end of its $950 million to $970 million forecast range.The equity research firm maintai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226016","title":"3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226016?lang=en_us&edition=fundamental","pubTime":"2026-07-21 12:51","pubTimestamp":1784609487,"startTime":"0","endTime":"0","summary":"Fast growing stocks with high insider ownership can be especially interesting when markets are wrestling with questions around inflation, interest rates and geopolitical risk. While oil prices, central bank decisions and mixed growth signals pull headlines in different directions, investors often look for companies where management and insiders are strongly aligned with shareholders and where growth potential is supported by optimistic analyst and internal views. This article highlights 3...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-trading-below-fair-value-with-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-trading-below-fair-value-with-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GEAR.AU","SLF.AU","STW.AU","VAP.AU","IOZ.AU","XJO.AU","DACE.AU","BK4139","OZR.AU","OZF.AU","GIVE.AU","BK7145","VAS.AU","BK7067","BBOZ.AU","IIGF.AU","TLX","XAO.AU","QRE.AU","ZYAU.AU","IISV.AU","E200.AU","IMLC.AU","QFN.AU","EIGA.AU","BK7104","GLF.AU","XKO.AU","TLX.AU","BEAR.AU","PDI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653428732","title":"Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653428732","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653428732?lang=en_us&edition=fundamental","pubTime":"2026-07-21 08:35","pubTimestamp":1784594126,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$19.00. Hester covers the Healthc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653416162","title":"Telix Pharmaceuticals Posts Higher Q2 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2653416162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653416162?lang=en_us&edition=fundamental","pubTime":"2026-07-21 07:09","pubTimestamp":1784588953,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  reported second-quarter revenue rose 21% to $247 million due to strong sale of precision medicine category, according to a Tuesday filing with the Australian bourse.The company expects fiscal 2026 revenue and other income to be more than $1 billion, with income tracking in line with the upper end of outlook of $950 million to $970 million.It increased its fiscal 2026 research and development expenditure outlook to $230 million to $270 million from prior range of $200 million to$240 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653246410","title":"Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653246410","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653246410?lang=en_us&edition=fundamental","pubTime":"2026-07-21 05:00","pubTimestamp":1784581200,"startTime":"0","endTime":"0","summary":"First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3330128/0/en/Telix-Doses-First-Patient-in-Phase-3-LUTEON-Trial-of-TLX250-Tx-for-Renal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","TLX","BK4526","ASX","BK4139","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652250486","title":"3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2652250486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652250486?lang=en_us&edition=fundamental","pubTime":"2026-07-20 03:20","pubTimestamp":1784488812,"startTime":"0","endTime":"0","summary":"With inflation readings softening in several major economies, bond yields pulling back from recent highs and energy prices back in focus, many investors are looking for growth stories where management has real skin in the game. The Fast Growing Stocks With High Insider Ownership screener targets companies that combine strong growth potential with leadership teams that are publicly optimistic about the outlook. In this article, you will see three stocks from that screener that stand out on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-worth-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","GIVE.AU","XJO.AU","SLF.AU","E200.AU","IISV.AU","DACE.AU","XAO.AU","IMLC.AU","QFN.AU","XKO.AU","VAS.AU","ZYAU.AU","OZF.AU","EIGA.AU","IOZ.AU","BK4139","QRE.AU","GEAR.AU","BEAR.AU","STW.AU","OZR.AU","TLX","PDI.AU","IIGF.AU","BK7104","VAP.AU","GLF.AU","TLX.AU","BK7145","BBOZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652402632","title":"RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2652402632","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652402632?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:26","pubTimestamp":1784283964,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals' (TLX) Australian stock has an average rating of buy and mean price target of AU$25.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652847265","title":"3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction","url":"https://stock-news.laohu8.com/highlight/detail?id=2652847265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652847265?lang=en_us&edition=fundamental","pubTime":"2026-07-17 12:57","pubTimestamp":1784264261,"startTime":"0","endTime":"0","summary":"With growth signals mixed across major economies and central banks pulling policy in different directions, many investors are looking for companies where management and outside analysts are broadly aligned on the outlook. That is exactly what the Fast Growing Stocks With High Insider Ownership screener focuses on, highlighting businesses with strong growth potential where insiders have meaningful skin in the game. This combination can help you focus on opportunities backed by both internal...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-where-insider-ownership-signals-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZYAU.AU","BK7067","VAP.AU","XKO.AU","GLF.AU","IISV.AU","IOZ.AU","OZR.AU","OZF.AU","GEAR.AU","TLX","QRE.AU","BK7104","XAO.AU","IMLC.AU","GIVE.AU","EIGA.AU","BEAR.AU","SLF.AU","PDI.AU","BBOZ.AU","STW.AU","XJO.AU","BK7145","IIGF.AU","DACE.AU","BK4139","TLX.AU","E200.AU","QFN.AU","VAS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652473490","title":"Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652473490","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652473490?lang=en_us&edition=fundamental","pubTime":"2026-07-17 08:45","pubTimestamp":1784249142,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has completed enrollment of 105 patients in its phase three registration study of TLX591-Px, a prostate cancer imaging agent, in Japan, according to a Friday statement by the company.The study will generate clinical data to support a new drug application submission to Japan's Pharmaceuticals and Medical Devices Agency, seeking approval for the use of the product in detecting metastatic lesions in patients with recurrent prostate cancer.The company's shares fell 2% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651916490","title":"Telix Pharmaceuticals Opens Radiopharmaceutical Research, Manufacturing, Treatment Facility in Melbourne","url":"https://stock-news.laohu8.com/highlight/detail?id=2651916490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651916490?lang=en_us&edition=fundamental","pubTime":"2026-07-16 10:53","pubTimestamp":1784170381,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) opened a multi-million dollar radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, described as a \"first-of-its-kind\" Australian purpose-bu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651973204","title":"3 ASX Growth Stocks Backed By Insiders That Could Reward Patient Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651973204","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651973204?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:39","pubTimestamp":1784158745,"startTime":"0","endTime":"0","summary":"With inflation pressures moving differently across regions and interest rate expectations constantly in focus, many investors are looking for companies where both analysts and insiders see room for growth. The Fast Growing Stocks With High Insider Ownership screener targets exactly that. It highlights businesses that pair strong growth potential with management teams that have meaningful skin in the game. This combination can help align your interests with those running the company. In this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-asx-growth-stocks-backed-by-insiders-that-could-reward-pat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-asx-growth-stocks-backed-by-insiders-that-could-reward-pat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","BK7104","LIN.AU","BK4139","BK7095","TLX.AU","BK7067","TLX","PDI.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":199,"code":"91000000","status":"200"}]}}